Medical Condition News

RSS

New information on efficacy of CLA in treating Crohn's disease

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

20 Mar 2012

Epidemiologist examines effect of population aging on inpatient care

The effect of population aging on the number of admissions to hospital for inpatient treatment is examined by epidemiologist Enno Nowossadeck in the latest issue of Deutsches -rzteblatt International.

20 Mar 2012

Two Cedars-Sinai physicians to receive ACC Distinguished Scientist Award

Two physicians from the Cedars-Sinai Heart Institute will receive the American College of Cardiology's highest honors for scientific research and clinical care during the organization's upcoming annual scientific meeting in Chicago.

20 Mar 2012

Single dose of X-ray radiation can prevent glaucoma

Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from glaucoma.

20 Mar 2012

Researchers discover new method to identify cancer-causing translocations

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report they have discovered a method to identify cancer-causing rearrangements of genetic material called chromosomal translocations quickly, accurately, and inexpensively.

20 Mar 2012

Health must be taken into account in climate change mitigation strategies

Health must be taken into account in climate change mitigation strategies. It is not widely appreciated that there are many benefits to health that are likely to accrue from a low carbon economy, say experts in a special supplement published on bmj.com today.

20 Mar 2012

Researchers identify Wnt pathway as new target for scleroderma therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

Groundbreaking cystic fibrosis clinical trial to proceed after renewed funding

The team of scientists based in Edinburgh, Oxford and London were developing a treatment which involves putting genes into the lungs of patients suffering the fatal, inherited wasting disease, passed early clinical trials in 2010. But the recession badly affected the Cystic Fibrosis Trust, the charity that had funded the programme, and work had to stop last year just as the consortium was closing in on its goal.

19 Mar 2012

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

The National Institute for Health and Clinical Excellence (Nice) issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The new drug can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterized by periods when symptoms worsen and then improve.

19 Mar 2012

$Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015$

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

19 Mar 2012

Boston Scientific lauds private insurance reimbursement coverage for bronchial thermoplasty

Boston Scientific Corporation welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed using the Alair Bronchial Thermoplasty System. Minnesota-based HealthPartners and Michigan-based Priority Health recently issued the first public postings of positive insurance coverage policies providing their respective memberships with reimbursement for this novel procedure to treat severe asthma.

19 Mar 2012

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting.

19 Mar 2012

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

A research team led by the University of Melbourne, Australia, has developed a novel technique that tracks diseased proteins behaving badly by forming clusters in brain diseases such as Huntington's and Alzheimer's.

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

FDA approves key testing phase for artificial pancreas

A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.

19 Mar 2012

FDA panel to review Cameron Health S-ICD System PMA application

Cameron Health, Inc. announced today that the U.S. Food and Drug Administration Circulatory System Devices Panel will review the Premarket Approval (PMA) application of the S-ICD System on April 26, 2012.

19 Mar 2012

Merz launches new, once daily Mederma Advanced Scar Gel

Mederma, the #1 doctor-and pharmacist-recommended brand for scars for over a decade, announced today the introduction of Mederma Advanced Scar Gel, which reduces the overall appearance of scars caused by injury, acne, surgery or burns with just one daily application. Mederma Advanced Scar Gel contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma® scar products and stretch marks therapy.

19 Mar 2012

Software tool accurately estimates risk of heart disease

University of Granada researchers have developed a software tool that makes an accurate estimation of the risk that a person has to suffer a heart disease. In addition, this software tool allows the performance of massive risk estimations, i.e. it helps estimating the risk that a specific population group has of suffering a heart condition. The researchers employed a sample including 3 000 patients.

19 Mar 2012

BSD-500 Hyperthermia System installed at Fort Belvoir Community Hospital

BSD Medical Corporation announced today the purchase, installation and acceptance of a BSD-500 Hyperthermia System (BSD-500) by Fort Belvoir Community Hospital (Fort Belvoir).

19 Mar 2012